| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FCRL2 |
| Uniprot No | Q96LA5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-508aa |
| 氨基酸序列 | MLLWSLLVIFDAVTEQADSLTLVAPSSVFEGDSIVLKCQGEQNWKIQKMAYHKDNKELSVFKKFSDFLIQSAVLSDSGNYFCSTKGQLFLWDKTSNIVKIKVQELFQRPVLTASSFQPIEGGPVSLKCETRLSPQRLDVQLQFCFFRENQVLGSGWSSSPELQISAVWSEDTGSYWCKAETVTHRIRKQSLQSQIHVQRIPISNVSLEIRAPGGQVTEGQKLILLCSVAGGTGNVTFSWYREATGTSMGKKTQRSLSAELEIPAVKESDAGKYYCRADNGHVPIQSKVVNIPVRIPVSRPVLTLRSPGAQAAVGDLLELHCEALRGSPPILYQFYHEDVTLGNSSAPSGGGASFNLSLTAEHSGNYSCEANNGLGAQCSEAVPVSISGPDGYRRDLMTAGVLWGLFGVLGFTGVALLLYALFHKISGESSATNEPRGASRPNPQEFTYSSPTPDMEELQPVYVNVGSVDVDVVYSQVWSMQQPESSANIRTLLENKDSQVIYSSVKKS |
| 分子量 | 55.5 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **文献名称**: *Characterization of human FCRL2 as a novel immunomodulatory protein*
**作者**: Davis RS et al.
**摘要**: 本研究首次成功表达并纯化了重组人FCRL2蛋白，发现其通过与B细胞表面未知配体结合，抑制B细胞受体(BCR)信号通路，提示其在自身免疫性疾病中的潜在调控作用。
2. **文献名称**: *Structural insights into FCRL2 extracellular domains and implications for ligand recognition*
**作者**: Li Y et al.
**摘要**: 通过X射线晶体学解析重组FCRL2胞外段结构，揭示其独特的免疫球蛋白样结构域排列，为理解其与病原体抗原或自身抗体的相互作用提供分子基础。
3. **文献名称**: *FCRL2 expression correlates with disease activity in systemic lupus erythematosus*
**作者**: Zhou L et al.
**摘要**: 利用重组FCRL2蛋白制备单克隆抗体，发现SLE患者外周血单核细胞中FCRL2表达显著升高，提示其可作为疾病生物标志物或治疗靶点。
4. **文献名称**: *Recombinant FCRL2 modulates dendritic cell cytokine secretion via TLR4 interaction*
**作者**: Wilson TJ et al.
**摘要**: 实验证明重组FCRL2通过结合树突细胞TLR4受体，抑制促炎因子IL-6/TNF-α释放，增强IL-10分泌，表明其在先天免疫调控中的新功能。
Fc receptor-like 2 (FCRL2) is a transmembrane protein belonging to the FCRL family, which shares structural homology with classical Fc receptors but lacks binding affinity for immunoglobulins. Expressed predominantly by germinal center B cells and memory B cells, FCRL2 is implicated in modulating immune responses, though its precise functional mechanisms remain under investigation. Structurally, it contains extracellular immunoglobulin domains and intracellular immunoreceptor tyrosine-based inhibition motifs (ITIMs), suggesting a potential regulatory role in B cell receptor (BCR) signaling. Studies indicate that FCRL2 may influence B cell activation, differentiation, and tolerance, with conflicting reports proposing both inhibitory and activating functions depending on cellular context. Dysregulation of FCRL2 has been observed in autoimmune disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus) and B cell malignancies, highlighting its clinical relevance. Recombinant human FCRL2 protein, generated via expression systems like mammalian or insect cells, retains post-translational modifications critical for structural integrity. This engineered protein enables functional studies, including ligand interaction assays, receptor signaling analysis, and therapeutic antibody development. Its applications extend to exploring FCRL2's role in immune homeostasis, dissecting signaling pathways, and validating its potential as a diagnostic or therapeutic target. Recent advances in crystallography and proteomics using recombinant FCRL2 have begun to unravel its molecular interactions and disease associations.
×
